KBC Group’s OptimizeRx OPRX Stock Holding History

KBC Group’s Portfolio OPRX Stock Details OPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,548	Closed	-$26K	–	1521
2022 Q4	$26K	Hold	1,548	–	–	﹤0.01%	1488
2022 Q3	$23K	Hold	1,548	–	–	﹤0.01%	1505
2022 Q2	$42K	Buy	+1,548	New	+$45.9K	﹤0.01%	1451

Other funds holding OPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

GIPM

G2 Investment Partners Management New York $549M AUM 179.59% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KBC Group's OPRX Position: Q1 2023 in Review

KBC Group sold out of OptimizeRx (OPRX) in Q1 2023, closing a stake of 1,548 shares — an estimated $26K sold.

KBC Group first reported a position in OPRX in Q2 2022 and held it in 3 quarters. The position peaked at $42K in Q2 2022. 110 funds tracked by Wall St. Rank hold OPRX as of Q1 2023.

KBC Group reported no remaining OptimizeRx position as of Q1 2023 after selling out during the quarter.
KBC Group sold 1,548 OptimizeRx shares in Q1 2023, an estimated $26K.
KBC Group first reported a position in OptimizeRx in Q2 2022 and held it in 3 quarters.
KBC Group's OptimizeRx position peaked at $42K in Q2 2022.
110 funds tracked by Wall St. Rank held OptimizeRx as of Q1 2023.

Based on KBC Group's 13F filing for Q1 2023, filed 4 May 2023.